NCT06717958 - Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

February 1, 2030

Conditions

AMLMDS

Interventions

DRUG

Ivosidenib 250 MG (milligram)

oral

Trial Locations (12)

NOT_YET_RECRUITING

Universitätsklinikum Aachen, Aachen

NOT_YET_RECRUITING

Technische Universitaet Dresden, Medizinische Klinik und Poliklinik I, Dresden

NOT_YET_RECRUITING

Universitätsklinikum Essen, Essen

RECRUITING

Martin-Luther-Universitaet Halle-Wittenberg, Halle

NOT_YET_RECRUITING

University Medical Center Hamburg-Eppendorf, Hamburg

NOT_YET_RECRUITING

Universitätsklinikum Jena, Jena

RECRUITING

Universitätsklinikum Schleswig-Holstein, Kiel

NOT_YET_RECRUITING

Universität Leipzig, Leipzig

NOT_YET_RECRUITING

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), München

NOT_YET_RECRUITING

Universität Münster, Münster

NOT_YET_RECRUITING

Rostock University Medical Center, Rostock

NOT_YET_RECRUITING

Universitaetsklinikum Ulm, Ulm

All Listed Sponsors

lead

Technische Universität Dresden

OTHER